

# **EXEL COMPOSITES**

Chemicals/ Finland, November 1, 2024 Company update

# Still recovering from the lows

Exel's Q3 figures disappointed due to the continued demand softness, however EBIT has plenty of potential next year.

#### Some investments projects have been further postponed


Exel's EUR 24.6m Q3 revenue grew 20% y/y but declined 8% q/q due to seasonality, as well as continued soft demand, and was below the EUR 26.5m/26.0m Evli/cons. estimates. The revenue disappointment also left the EUR 0.7m adj. EBIT lower than the EUR 1.5m/1.0m Evli/cons. estimates. Q3 order intake declined 8% y/y, yet order backlog was still 7% higher y/y. Many investment decisions are being postponed, which seems at least to some extent be due to the POTUS election, but the low comparison period means it shouldn't be too hard for Exel to achieve continued y/y growth in Q4. Exel thus continues to guide y/y higher FY'24 revenue even if the YTD'Q3 figure remained flat.

#### Some cuts to estimates, but growth likely to continue

We revise our Q4 y/y growth estimate down by 600bps due to the demand softness seen in Q3, yet we still estimate significant 16% growth. Exel FY'24 revenue would then grow a little over 3% y/y. We cut our Q4 EBIT estimate by EUR 0.9m, which would leave FY'24 adj. EBIT at a very modest level of EUR 2.4m. We also revise our FY'25 estimates down, but Exel should be able to grow at a high single—digit rate next year as the new Indian factory begins production in Q4'24. We expect Energy to be the only customer industry not able to grow this year, but it should have solid ground from which to expand next year thanks to wind power demand in India as well as China (where an offshore wind system order was recently signed). Meanwhile Transportation and Industrial are already improving; Exel has made progress with post—processing services and new customers in the US.

#### Significant earnings recovery should continue next year

We estimate 6% EBIT margin for FY'25, which would represent further significant earnings recovery driven by higher volumes. Exel is valued slightly below 9x EV/EBIT on our EUR 6.4m EBIT estimate for FY'25, which isn't a very low multiple, but the earnings level would be quite moderate relative to historical performance and potential. We don't hence view valuation challenging even if demand uncertainty persists. Our new TP is EUR 0.38 (0.40) as we retain BUY rating.



BUY HOLD SELL

<b>KEY FIGUR</b>	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2022	137.0	3.0	2.2%	7.8	0.04	30.1	0.7	31.4	12.0%	0.05
2023	96.8	-4.9	-5.0%	-0.8	-0.19	-3.2	0.6	-12.6	-2.7%	
2024E	100.1	2.1	2.1%	10.0	-0.02	-20.4	0.6	27.5	27.2%	
2025E	107.1	6.4	6.0%	1.9	0.02	15.2	0.5	8.8	5.1%	0.01
2026E	112.5	8.4	7.5%	3.6	0.06	5.4	0.5	6.4	9.7%	0.01
Market c	ap, EURm		37	Gearing 2024	IE, %	135	5.8 % CAGR	EPS 2023-2	26, %	0.0 %
Net debt	2024E, EUR	m	22	Price/book 2	024E		2.3 CAGR	Sales 2023-	-26, %	5.1 %
Enterpris	se value, EUF	Rm	58	Dividend yield	1 2024E, %	(	0.0 % ROE 2	024E, %		-10.7 %
Total ass	ets 2024E, E	URm	74	Tax rate 2024	4E, %	-3:	1.3 % ROCE	2024E, %		2.1 %
Goodwill	2024E, EURr	n	13	Equity ratio 2	024E, %	2	1.4 % PEG, F	P/E 24/CAGF	3	0.0

All the important disclosures can be found on the last pages of this report.

# **EXEL COMPOSITES**

# Chemicals/Finland, November 1, 2024 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMP	TIONS ASSUMPTIONS FOR WACC
Current share price	0.35 PV of Free Cash Flow	102 Long-term growth, %	1.5 % Risk-free interest rate, % 2.25
DCF share value	1.84 PV of Horizon value	126 WACC, %	8.5 % Market risk premium, % 5.8
Share price potential, %	434.4 % Unconsolidated equity	0 Spread, %	0.5 % Debt risk premium % 3.3
Maximum value	2.0 Marketable securities	11 Minimum WACC, %	8.0 % Equity beta coefficient 1.0
Minimum value	1.7 Debt — dividend	-43 Maximum WACC, %	9.0 % Target debt ratio, %
Horizon value, %	55.3 % Value of stock	197 No. of shares, Mn	106.7 Effective tax rate, %

DCF valuation, EURm	2023	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	TERMINAL
Net sales	97	100	107	113	115	117	119	122	124	127	129	131
Sales growth (%)	_ 29.3%	3.4%	7.0%	5.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	1.5%	1.5%
Operating income (EBIT)	-5	2	6	8	11	12	13	14	14	14	14	14
Operating income margin %	-5.0%	2.1%	6.0%	7.5%	10.0%	10.0%	11.0%	11.5%	11.5%	11.0%	11.0%	11.0%
+ Depreciation+amort.	9	6	6	7	6	6	5	5	5	5	5	
EBITDA	4	8	13	16	18	17	18	19	19	19	19	
<ul> <li>Paid taxes</li> </ul>	0	1	-2	3	4	4	4	4	4	4	4	
<ul> <li>Change in NWC</li> </ul>	3	11	-2	-6	0	0	Ø	0	0	0	0	
NWC / Sales, %	11.7%	0.7%	2.7%	7.8%	7.8%	7.8%	7.8%	7.8%	7.8%	7.8%	7.8%	
+ Change in other liabs	0											
<ul> <li>Operative CAPEX</li> </ul>	-4	-4	-4	-4	-4	-4	-4	-5	-5	-5	-5	
opCAPEX / Sales, %	4.0%	4.8%	4.3%	4.2%	3.9%	3.9%	3.9%	3.9%	3.9%	3.9%	3.8%	
<ul> <li>Acquisitions</li> </ul>												
+ Divestments												
- Other items												
= FOFF	4	15	4	8	17	16	18	19	19	18	19	268
= Discounted FCFF		15	4	7	13	12	12	11	10	9	9	126
= DFCF min WACC		15	4	7	13	12	12	12	11	10	9	142
= DFCF max WACC		15	4	7	13	11	11	11	10	9	8	113

### Sensitivity analysis, EUR

### **Terminal WACC**

Terminal EBIT-%

	6.53 %	7.53 %	8.53 %	9.53 %	10.53 %
9.00 %	2.44	2.00	1.68	1.44	1.26
10.00 %	2.57	2.10	1.76	1.51	1.31
11.00 %	2.71	2.20	1.84	1.57	1.36
12.00 %	2.84	2.31	1.93	1.64	1.42
13.00 %	2.98	2.41	2.01	1.71	1.47

# **EXEL COMPOSITES**

Chemicals/Finland, November 1, 2024 Company update

# **Estimates and valuation**

Exel Composites	Q1'23	Q2'23	Q3'23	Q4'23	2023	Q1'24	Q2'24	Q3'24	Q4'24e	2024e
Buildings and infrastructure	5.7	5.0	4.3	3.7	18.7	4.8	5.5	5.7	4.7	20.7
Industrial	5.5	3.4	3.0	3.5	15.4	3.4	4.2	3.8	4.2	15.5
Energy	6.2	5.4	5.2	4.9	21.8	5.3	4.5	4.9	4.9	19.6
Transportation	4.4	4.0	3.3	4.7	16.3	3.9	5.0	4.0	5.3	18.1
Other	7.1	7.6	4.7	5.3	24.7	6.0	7.5	6.2	6.6	26.2
Revenue	28.8	25.4	20.5	22.1	96.8	23.4	26.6	24.6	25.6	100.1
y/y change, %	-16 %	-33 %	-39 %	-29 %	-29 %	-19 %	5 %	20 %	16 %	3 %
Adjusted EBIT	0.0	0.1	-1.2	-1.3	-2.4	-0.6	1.4	0.7	0.9	2.4
EBIT	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	0.6		2.1
-margin, %	0.0 %	0.3 %	-5.9 %	-5.9 %	-2.5 %	-2.4 %	<i>5.2 %</i>	2.9 %	3.5 %	2.4 %
-margin (reported), %	-1.0 %	-1.0 %	-3.2 %	-16.7 %	-5.0 %	-2.4 %	4.4 %	2.5 %		2.1 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	23	24	25	23	24	25	23	24	25
Hexagon Composites	747	16.4x	17.2x	11.4x	33.5x	31.4x	16.5x	4.2 %	6.3 %	10.1 %
Hexcel	4407	19.6x	15.1x	13.2x	31.5x	23.7x	19.4x	12.1 %	12.5 %	14.0 %
Avient	4008	10.8x	11.3x	10.4x	17.4x	17.8x	15.6x	10.0 %	10.4 %	11.3 %
SGL Carbon	573	6.9x	5.5x	3.6x	8.4x	8.3x	5.5x	10.1 %	7.5 %	10.8 %
TPI Composites	149		255.4x	7.4x			12.9x	-10.9 %	-3.7 %	3.5 %
Gurit Holding	95	12.7x	4.4x	3.9x	22.2x	6.6x	5.7x	4.3 %	5.3 %	5.8 %
Peer Group Average	1663	13.3x	51.5x	8.3x	22.6x	17.6x	12.6x	5.0 %	6.4 %	9.3 %
Peer Group Median	660	12.7x	13.2x	8.9x	22.2x	17.8x	14.3x	7.1 %	6.9 %	10.4 %
Exel Composites (Evli est.)	37	16.0x	7.2x	4.4x	-12.6x	27.5x	8.8x	-5.0 %	2.1 %	6.0 %

-50 %

-157%

*55* %

-38 %

-170 %

-69 %

-42 %

26 %

-46 %

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

# **EXEL COMPOSITES**

# Chemicals/Finland, November 1, 2024 Company update

#### INTERIM FIGURES

EVLI ESTIMATES, EURM	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3	2024Q4E	2024E	2025E	2026E
Net sales	28.8	25.4	20.5	22.1	96.8	23.4	26.6	24.6	25.6	100.1	107.1	112.5
EBITDA	1.5	1.4	1.1	-0.2	3.8	0.9	2.6	2.2	2.4	8.1	12.8	15.7
EBITDA margin (%)	5.3%	5.7%	5.2%	-0.8%	4.0%	3.8%	9.8%	9.0%	9.4%	8.1%	11.9%	13.9%
EBIT	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	0.6	0.9	2.1	6.4	8.4
EBIT margin (%)	-1.0%	-1.0%	-3.2%	-16.7%	-5.0%	-2.4%	4.4%	2.5%	3.5%	2.1%	6.0%	7.5%
Net financial items	-1.2	-0.4	0.2	-2.0	-3.4		-0.4	-2.4	-0.8	-3.5	-3.0	-3.2
Pre-tax profit	-1.5	-0.7	-0.4	-5.7	-8.3	-0.6	0.8	-1.8	0.2	-1.4	3.4	5.2
Tax	-0.7	-0.3	-0.2	0.0	-1.1		-0.3	-0.1	-0.1	-0.4	-1.0	1.6
Tax rate (%)	-43.8%	-36.3%	-48.2%	0.8%	-12.8%		32.2%	-4.3%	66.7%	-31.3%	29.2%	-31.3%
Net profit	-2.1	-0.9	-0.6	-5.6	-9.3	-0.6	0.5	-1.8	0.1	-1.8	2.4	6.9
EPS	-0.04	-0.02	-0.01	-0.11	-0.19	-0.01	0.01	-0.02	0.00	-0.02	0.02	0.06
EPS adj. (diluted)	-0.04	-0.02	-0.01	-0.11	-0.19	-0.01	0.01	-0.02	0.00	-0.02	0.02	0.06
Dividend per share											0.01	0.01
SALES, EURm	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3	2024Q4E	2024E	2025E	2026E
Exel Composites	28.8	25.4	20.5	22.1	96.8	23.4	26.6	24.6	25.6	100.1	107.1	112.5
Total	28.8	25.4	20.5	22.1	96.8	23.4	26.6	24.6	25.6	100.1	107.1	112.5
SALES GROWTH, Y/Y %	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3	2024Q4E	2024E	2025E	2026E
Exel Composites	-15.7%	-33.3%	-39.2%	-28.8%	-29.3%	-18.9%	4.7%	19.7%	16.0%	3.4%	7.0%	5.0%
Total	-15.7%	-33.3%	-39.2%	-28.8%	-29.3%	-18.9%	4.7%	19.7%	16.0%	3.4%	7.0%	5.0%
EBIT, EURm	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3	2024Q4E	2024E	2025E	2026E
Exel Composites	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	0.6	0.9	2.1	6.4	8.4
Total	-0.3	-0.2	-0.7	-3.7	-4.9	-0.6	1.2	0.6	0.9	2.1	6.4	8.4
EBIT margin %	2023Q1	2023Q2	2023Q3	2023Q4	2023	2024Q1	2024Q2	2024Q3	2024Q4E	2024E	2025E	2026E
Exel Composites	-1.0%	-1.0%	-3.2%	-16.7%	-5.0%	-2.4%	4.4%	2.5%	3.5%	2.1%	6.0%	7.5%
Total	-1.0%	-1.0%	-3.2%	-16.7%	-5.0%	-2.4%	4.4%	2.5%	3.5%	2.1%	6.0%	7.5%

# **EXEL COMPOSITES**

# Chemicals/Finland, November 1, 2024 Company update

INCOME STATEMENT, EURM	2019	2020	2021	2022	2023	2024E	2025E	2026E
Sales	103.8	108.6	134.4	137.0	96.8	100.1	107.1	112.5
Sales growth (%)	7.5%	4.6%	23.7%	2.0%	-29.3%	3.4%	7.0%	5.0%
EBITDA	10.7	15.3	11.9	10.1	3.8	8.1	12.8	15.7
EBITDA margin (%)	10.3%	14.1%	8.9%	7.4%	4.0%	8.1%	11.9%	13.9%
Depreciation	-5.6	-5.9	-8.2	-7.1	-8.7	-6.0	-6.4	-7.2
EBITA	5.1	9.4	3.7	3.0	-4.9	2.1	6.4	8.4
Goodwill amortization / writedown								
EBIT	5.1	9.4	3.7	3.0	-4.9	2.1	6.4	8.4
EBIT margin (%)	4.9%	8.7%	2.8%	2.2%	-5.0%	2.1%	6.0%	7.5%
Reported EBIT	5.1	9.4	3.7	3.0	-4.9	2.1	6.4	8.4
EBIT margin (reported) (%)	4.9%	8.7%	2.8%	2.2%	-5.0%	2.1%	6.0%	7.5%
Net financials	-1.2	-2.3	0.4	0.6	-3.4	-3.5	-3.0	-3.2
Pre-tax profit	3.9	7.1	4.2	3.6	-8.3	-1.4	3.4	5.2
Taxes	-1.5	-1.8	-2.5	-1.5	-1.1	-0.4	-1.0	1.6
Minority shares								
Net profit	2.4	5.4	1.7	2.1	-9.3	-1.8	2.4	6.9
Cash NRIs								
Non-cash NRIs								
BALANCE SHEET, EURM								
Assets								
Fixed assets	23	30	34	31	25	24	22	19
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	5	3	3	2	1	1	2	2
Inventory	17	16	24	23	17	12	14	17
Receivables	20	21	26	24	18	13	14	18
Liquid funds	7	12	16	17	11	11	13	14
Total assets	85	97	118	113	85	74	78	83
Liabilities								
Shareholders' equity	26	29	31	30	18	16	18	24
Minority interest								
Convertibles								
Lease liabilities	4	2	2	1	0	1	2	2
Deferred taxes	0	0	0	1	0	0	0	0
Interest bearing debt	32	40	50	46	42	32	31	29
Non-interest bearing current liabilities	21	24	32	26	22	23	24	25
Other interest-free debt	2	2	3	9	3	3	3	3
Total liabilities	85	97	118	113	85	74	78	83
CASH FLOW, EURm								
+ EBITDA	11	15	12	10	4	8	13	16
Net financial items	-1	-2	0	1	-3	-4	-3	-3
- Taxes	-1 -2	-2	-3	-1	_3 0	_4 Ø	-5 -1	_3 2
Increase in Net Working Capital	_ <u>_</u>	3	-5 -5	3	3	11	-1 -2	-6
+/- Other	Τ.	J	J	J	J	TT	_	J
= Cash flow from operations	8	13	5	13	3	15	7	8
- Capex	-8	-13	-11	<u>-</u> 5	-4	<u>-</u> 5	-5	-5
- Acquisitions	U	10	11	J	-	J	0	J
+ Divestments								
= Free cash flow	1	0	-6	8	-1	10	2	4
+/- New issues/buybacks	0	-1	3	-1	-1 -1	10	_	4
<ul><li>Paid dividend</li></ul>	2	-1 2	2	-1 2	-1		1	1
+/- Other	3	7	9	-3	-2	-10	0	1 -2
Change in cash	2	5	4	-3 2	- <u>c</u> -6	-10	2	- <u>-</u> 2
Change III cash	۷	J	4	_	-0	v	۷	1

# **EXEL COMPOSITES**

# Chemicals/Finland, November 1, 2024 Company update

KEY FIGURES	2020	2021	2022	2023	2024E	2025E	2026E
M-cap	88	94	64	30	37	37	37
Net debt (excl. convertibles)	30	36	30	32	22	20	17
Enterprise value	118	131	94	61	58	57	54
Sales	109	134	137	97	100	107	113
BITDA	15	12	10	4	8	13	16
BIT	9	4	3	-5	2	6	8
Pre-tax	7	4	4	-8	-1	3	5
Earnings	5	2	2	_9	-2	2	7
Equity book value (excl. minorities)	29	31	30	18	16	18	24
equity book value (exol. millor tios)	20	01	00	10	10	10	
Valuation multiple	2020	2021	2022	2023	2024E	2025E	2026E
EV/Sales	1.1	1.0	0.7	0.6	0.6	0.5	0.5
EV/EBITDA	7.7	10.9	9.3	16.0	7.2	4.4	3.5
EV/EBITA	12.5	34.9	31.4	-12.6	27.5	8.8	6.4
EV/EBIT	12.5	34.9	31.4	-12.6	27.5	8.8	6.4
EV/OCF	8.8	27.2	7.4	19.6	3.9	8.6	6.5
EV/FOF	52.9	-26.0	12.5	17.5	3.8	12.6	6.6
P/FOFR P/E	754.8 16.4	-64.5 57.0	35.0 30.1	−157.6 −3.2	3.7 -20.4	19.5 15.2	10.3 5.4
P/BV	3.1	3.0	30.1 2.1	−3.≥ 1.7	-20.4 2.3	15.2 2.0	5.4 1.5
rarget EV/EBITDA	0.1	۵.۷	∠.1	1.1	2.3 7.7	2.0 4.7	3.7
Target EV/EBIT					29.3	9.4	6.8
Target EV/FCFF					6.2	31.8	16.2
Target P/BV					2.5	2.2	1.7
Target P/E, diluted	15.2	62.4	10.0	-4.0	-22.4	16.7	5.9
Per share measures	2020	2021	2022	2023	2024E	2025E	2026E
Number of shares (million)	50.13	50.13	50.13	50.13	106.69	106.69	106.69
, ,							
lumber of shares (diluted, million)	50.13	50.13	50.13	50.13	106.69	106.69	106.69
EPS .	0.11	0.03	0.04	-0.19	-0.02	0.02	0.06
Operating cash flow per share	0.27	0.10	0.25	0.06	0.14	0.06	0.08
Free cash flow per share	0.01	-0.12	0.15	-0.02	0.09	0.02	0.03
Book value per share	0.57	0.62	0.61	0.35	0.15	0.17	0.23
Dividend per share	0.05	0.05	0.05			0.01	0.01
Dividend payout ratio, %	44.3%	143.7%	110.9%			43.9%	15.6%
Dividend yield, %	2.7%	2.5%	3.7%			2.9%	2.9%
CF yield, %	0.6%	-6.5%	12.0%	-2.7%	27.2%	5.1%	9.7%
:fficiency measures	2020	2021	2022	2023	2024E	2025E	2026E
ROE	19.5%	5.5%	7.0%	-38.7%	-10.7%	14.2%	32.3%
ROCE	14.4%	5.1%	4.0%	-8.8%	2.1%	10.9%	13.8%
Financial ratios	2020	2021	2022	2023	2024E	2025E	2026E
Inventories as % of sales	14.9%	17.8%	17.1%	17.4%	12.0%	13.0%	15.5%
Receivables as % of sales	19.3%	19.6%	17.8%	18.1%	12.5%	13.5%	16.0%
Non-int. bearing liabilities as % of sales	22.0%	23.8%	19.2%	22.7%	22.7%	22.7%	22.7%
NWC/sales, %	11.2%	12.7%	10.3%	11.7%	0.7%	2.7%	7.8%
Operative CAPEX/Sales, %	11.9%	8.2%	3.6%	4.0%	4.8%	4.3%	4.2%
DAPEX/sales (incl. acquisitions), %	11.9%	8.2%	3.6%	4.0%	4.8%	4.3%	4.2%
FCFF/EBITDA	0.1	-0.4	0.7	0.9	1.9	0.3	0.5
	2.0	3.0	2.9	8.2	2.7	1.5	1.1
Net Debt/EBITDA, book—weighted							0.0
	0.5	0.5	0.7	1.4	0.9	0.8	0.8
Net Debt/EBITDA, book—weighted Debt/equity, market—weighted Equity ratio, book—weighted		0.5 0.3	0.7 0.3	1.4 0.2	0.9 0.2	0.8 0.2	0.8 0.3

# **EXEL COMPOSITES**

## Chemicals/Finland, November 1, 2024 Company update

**COMPANY DESCRIPTION:** Exel Composites manufactures composites profiles for various demanding, mainly industrial end—use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

**INVESTMENT CASE:** Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	%
Erikoissijoitusrahasto Aktia Mikro Markka	6 866 856	2.369	6.4 %
OP-Finland Small Firms Fund	5 446 457	1.879	5.1 %
Elo Mutual Pension Insurance Company	5 123 275	1.768	4.8 %
Danske Invest Finnish Equity Fund	4 707 032	1.624	4.4 %
Phoebus Fund	3 780 000	1.304	3.5 %
Säästöpankki Pienyhtiöt	3 080 659	1.063	2.9 %
Proprius partners micro finland (non-ucits)	2 930 971	1.011	2.7 %
Nelimarkka Heikki Antero	1 913 463	0.660	1.8 %
Veritas Pension Insurance Company Ltd.	1 890 009	0.652	1.8 %
Suutarinen Timo	1 440 000	0.497	1.3 %
Ten largest	37 178 722	12.827	34.8 %
Residual	69 507 278	23.980	65.2 %
Total	106 686 000	36.807	100%

E/	١RI	NIN	GS	C	ΑL	E.	ND/	۱R

February 14, 2025 May 08, 2025 August 14, 2025 November 06, 2025 FY 2024 Results Q1 report Q2 report

Q3 report

OTHER EVENTS

#### **COMPANY MISCELLANEOUS**

CEO: Paul Sohlberg CFO: Mikko Rummukainen IR: Lilli Riikonen Mäkituvantie 5 01510 Vantaa Tel: +358 20 7541 200

# **EXEL COMPOSITES**

# Chemicals/Finland, November 1, 2024 Company update

#### **DEFINITIONS**

P/E	EPS
Price per share Earnings per share	Profit before extraord. items and taxes – income taxes + minority interest  Number of shares
Price per share  Shareholder's equity + taxed provisions per share	DPS  Dividend for the financial period per share
Market cap  Price per share * Number of shares	OCF (Operating cash flow)  EBITDA — Net financial items — Taxes — Increase in working capital — Cash NRIs ± Other adjustments
EV (Enterprise value)  Market cap + net debt + minority interest at market value  - share of associated companies at market value	FCF (Free cash flow)  Operating cash flow – Operative CAPEX – acquisitions + divestments
EV/Sales  Enterprise value Sales	FCF yield, %  Free cash flow  Market cap
Enterprise value  Enterprise value  Earnings before interest, tax, depreciation and amortization	Operative CAPEX / Sales  Capital expenditure – divestments – acquisitions Sales
Enterprise value Operating profit	Net working capital  Current assets — current liabilities
Net debt  Interest bearing debt – financial assets	Capital employed / Share  Total assets – non-interest bearing debt  Number of shares
<b>Total assets</b> Balance sheet total	Gearing  Net debt  Equity
Div yield, %  Dividend per share Price per share	Debt/Equity, %  Interest bearing debt  Shareholders' equity + minority interest + taxed provisions
Payout ratio,%  Total dividends  Earnings before extraordinary items and taxes  – income taxes + minority interest	Equity ratio. %  Shareholders' equity + minority interest + taxed provisions  Total assets – interest–free loans
Profit before extraordinary items + interest expenses + other financial costs Balance sheet total - non-interest bearing debt (average)	CAGR, %  Cumulative annual growth rate = Average growth rate per year
ROE, %  Profit before extraordinary items and taxes – income taxes  Shareholders' equity + minority interest + taxed provisions (average)	

## EXEL COMPOSITES

### Chemicals/Finland, November 1, 2024 Company update

#### **Important Disclosures**


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. The valuation assumptions used are sensitive to changes and can significantly affect fair values. A change of a single percentage point in any used assumption could affect fair values by more than +/-20%. Recommendations and changes by analysts are available at Analusts' recommendations and ratings revisions.

Investment recommendations are defined as follows:

Target price compared to share price < -10 % -10 - (+10) %> 10 %

Recommendation SELL HOLD BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage on the 23rd of October, 2024. If recommendation is not given, it is not mentioned here

#### Name(s) of the analust(s): Joonas Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [1.11.2024, 8:55]. This report has been published on [1.11.2024, 9:20].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

According to ERP's best knowledge, the issuer(s) of the securities does/(do) not hold in excess of 5% of the total issued share capital of the issuer(s).

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or -events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

### **EXEL COMPOSITES**

### Chemicals/Finland, November 1, 2024 Company update

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers FactSet and Bloomberg, stock—exchange releases from the companies and other company news, and publicly available online sources. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker—dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker—dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non—U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

# **EXEL COMPOSITES**

Chemicals/Finland, November 1, 2024 Company update

#### **Contact information**

#### SALES, TRADING AND RESEARCH

#### Equity Sales & Trading

 Joachim Dannberg (head)
 +358 9 4766 9123

 Aleksi Jalava
 +358 9 4766 9123

 Pasi Väisänen
 +358 9 4766 9123

#### **Evli Investment Solutions**

Johannes Asuja +358 9 4766 9205

#### **Equity Research**

 Jerker Salokivi (head)
 +358 9 4766 9149

 Joonas Ilvonen
 +358 44 430 9071

 Atte Jortikka
 +358 40 054 3725

 Atte Pítkäjärvi
 +358 44 047 6597



EVLI PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI PLC, STOCKHOLMSFILTAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000